[
    [
        {
            "time": "",
            "original_text": "养老目标基金总规模200亿最高赚15% 怎么投资的？",
            "features": {
                "keywords": [
                    "养老目标基金",
                    "规模",
                    "投资"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "养老目标基金总规模200亿最高赚15% 怎么投资的？",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "从仿制走向创新，恒瑞、豪森等的创新路径有何差异？",
            "features": {
                "keywords": [
                    "恒瑞",
                    "豪森",
                    "创新路径"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "从仿制走向创新，恒瑞、豪森等的创新路径有何差异？",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "艾迪药业IPO：管理费高企研发不足 供应商竟有个体户",
            "features": {
                "keywords": [
                    "艾迪药业",
                    "IPO",
                    "管理费",
                    "研发不足"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "艾迪药业IPO：管理费高企研发不足 供应商竟有个体户",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药(600276.SH)：国家药监局已受理氟唑帕利胶囊的药品注册申请",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "药监局",
                    "氟唑帕利胶囊",
                    "药品注册申请"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)：国家药监局已受理氟唑帕利胶囊的药品注册申请",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "基金三季报持仓报告，透露了哪些配置信息？",
            "features": {
                "keywords": [
                    "基金",
                    "三季报",
                    "持仓报告",
                    "配置信息"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "基金三季报持仓报告，透露了哪些配置信息？",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "突破4000亿市值后 恒瑞又一重磅新药获批！本土药企VS老牌MNC",
            "features": {
                "keywords": [
                    "恒瑞",
                    "市值",
                    "重磅新药",
                    "获批",
                    "本土药企",
                    "MNC"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "突破4000亿市值后 恒瑞又一重磅新药获批！本土药企VS老牌MNC",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[国盛证券张金洋团队]恒瑞医药：两大品种申报上市，在研管线超预期推进",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "品种申报",
                    "在研管线",
                    "推进"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[国盛证券张金洋团队]恒瑞医药：两大品种申报上市，在研管线超预期推进",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物单抗行业深度系列：靶点篇，马千里",
            "features": {
                "keywords": [
                    "医药生物",
                    "单抗",
                    "靶点",
                    "行业深度"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "医药生物单抗行业深度系列：靶点篇，马千里",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "融资余额6连升 猪周期概念股获增持逾11亿元",
            "features": {
                "keywords": [
                    "融资余额",
                    "猪周期",
                    "概念股",
                    "增持"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "农业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "融资余额6连升 猪周期概念股获增持逾11亿元",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[医药]公募基金三季报发布，医药继续处于超配状态——医药行业周报——中性（联系人：徐勇、甘英健、陈晨、张山峰）",
            "features": {
                "keywords": [
                    "公募基金",
                    "三季报",
                    "医药",
                    "超配状态"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[医药]公募基金三季报发布，医药继续处于超配状态——医药行业周报——中性（联系人：徐勇、甘英健、陈晨、张山峰）",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]